@article{2a72ca8d43fa44309cfbd0760717683d,
title = "Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: The viktory umbrella trial",
abstract = "The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify patients with metastatic gastric cancer based on clinical sequencing and focused on eight different biomarker groups (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, MET overexpression, all negative, TSC2 deficient, or RIC-TOR amplification) to assign patients to one of the 10 associated clinical trials in second-line (2L) treatment. Capivasertib (AKT inhibitor), savolitinib (MET inhibitor), selumetinib (MEK inhibitor), ada-vosertib (WEE1 inhibitor), and vistusertib (TORC inhibitor) were tested with or without chemotherapy. Seven hundred seventy-two patients with gastric cancer were enrolled, and sequencing was successfully achieved in 715 patients (92.6%). When molecular screening was linked to seamless immediate access to parallel matched trials, 14.7% of patients received biomarker-assigned drug treatment. The biomarker-assigned treatment cohort had encouraging response rates and survival when compared with conventional 2L chemotherapy. Circulating tumor (ctDNA) analysis demonstrated good correlation between high MET copy number by ctDNA and response to savolitinib. SIGNIFICANCE: Prospective clinical sequencing revealed that baseline heterogeneity between tumor samples from different patients affected response to biomarker-selected therapies. VIKTORY is the first and largest platform study in gastric cancer and supports both the feasibility of tumor profiling and its clinical utility.",
author = "Jeeyun Lee and Kim, {Seung Tae} and Kyung Kim and Hyuk Lee and Iwanka Kozarewa and Mortimer, {Peter G.S.} and Odegaard, {Justin I.} and Harrington, {Elizabeth A.} and Juyoung Lee and Taehyang Lee and Oh, {Sung Yong} and Kang, {Jung Hun} and Kim, {Jung Hoon} and Youjin Kim and Ji, {Jun Ho} and Kim, {Young Saing} and Lee, {Kyoung Eun} and Jinchul Kim and Sohn, {Tae Sung} and An, {Ji Yeong} and Choi, {Min Gew} and Lee, {Jun Ho} and Bae, {Jae Moon} and Sung Kim and Kim, {Jae J.} and Min, {Yang Won} and Min, {Byung Hoon} and Kim, {Nayoung K.D.} and Sally Luke and Kim, {Young Hwa} and Hong, {Jung Yong} and Park, {Se Hoon} and Park, {Joon Oh} and Park, {Young Suk} and Lim, {Ho Yeong} and Amirali Talasaz and Hollingsworth, {Simon J.} and Kim, {Kyoung Mee} and Kang, {Won Ki}",
note = "Funding Information: This work was supported by funding from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C3418). Support was also provided by a grant from the 20 by 20 Project of Samsung Medical Center (GF01140111). This investigator-initiated trial was also funded by a study-drug donation and partial fund from AstraZeneca. Funding Information: We would like to thank Drs. Adam J. Bass, Joseph Chao, and Samuel J. Klempner for scientific discussion and critical review of our manuscript. On behalf of the VIKTORY team, we would like thank our patients and their families for their participation. This work was supported by funding from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C3418). Support was also provided by a grant from the 20 by 20 Project of Samsung Medical Center (GF01140111). This investigator-initiated trial was also funded by a study-drug donation and partial fund from AstraZeneca. Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",
year = "2019",
month = oct,
doi = "10.1158/2159-8290.CD-19-0442",
language = "English",
volume = "9",
pages = "1388--1405",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "10",
}